ATRC — AtriCure, Inc.

AtriCure Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $140.5 million, up 13.1% year-over-year (12.1% on a constant currency basis).
• Full Year 2025 Revenue: $534 million, reflecting a 15% increase over 2024, exceeding guidance of 11%-13%.
• Adjusted EBITDA: $19.9 million for Q4, compared to $12.7 million in Q4 2024; full year adjusted EBITDA reached $61.8 million, up from $31.1 million in 2024.
• Net Income: $1.8 million for Q4, a significant improvement from a net loss of $15.6 million in Q4 2024; full year loss per share improved to $0.24 from $0.95 in 2024.
• Cash Generation: Approximately $45 million for the year, ending with $167.4 million in cash and investments.

2. Strategic Updates and Business Highlights

• Product Launches: Successful introduction of the cryoSPHERE MAX Probe and AtriClip FLEX-Mini, contributing to revenue growth in pain management and appendage management.
• Clinical Trials: Completed enrollment in the LeAAPS trial with over 6,500 patients, focusing on AtriClip devices for non-AF patients undergoing cardiac surgery. Initiated the BoxX-NoAF trial, targeting postoperative Afib in non-AF patients.
• Franchise Performance:
  • Pain Management: 24% growth in Q4, 33% for the full year.
  • Appendage Management: 15% growth in Q4, 19% for the full year, driven by AtriClip FLEX-Mini.
  • Afib Ablation: Open ablation grew over 17% for both Q4 and full year, primarily due to the EnCompass Clamp.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $600 million and $610 million, translating to 12%-14% growth.
• Adjusted EBITDA Guidance: Anticipated range of $80 million to $82 million.
• Market Focus: Continued emphasis on pain management and open appendage management growth, while expecting a decline in minimally invasive ablation revenue, albeit at a moderated rate.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: New entrants in the AtriClip market could impact growth; however, management views this as validation of the market's potential.
• U.K. Market Decline: Sales in the U.K. were negatively impacted by funding and reimbursement uncertainties, particularly affecting pain management and minimally invasive ablation.
• Hybrid Ablation Business: Experienced a 26% decline in 2025, with expectations for continued pressure in 2026.

5. Notable Q&A Insights

• Competitive Landscape: Management expressed confidence in AtriCure's established market position and ongoing innovation, viewing new competitors as a validation of market potential.
• LeAAPS Trial Data: No specific timeline for data release; the trial continues to receive positive assessments from the data safety monitoring board.
• Open Ablation Market Potential: Only about 20% of Afib patients undergoing CABG currently receive treatment, indicating significant growth potential.
• Training for New Products: The rollout of cryoXT is being approached cautiously, focusing on thorough training and adoption in select accounts before broader expansion.

Overall, AtriCure reported strong financial performance in 2025, driven by innovative product launches and strategic clinical trials, while navigating competitive pressures and market challenges. The outlook for 2026 remains positive, with expectations for continued growth and profitability.